MA32480B1 - Compositions pédiatriques pour le traitement de la sclérose en plaques - Google Patents

Compositions pédiatriques pour le traitement de la sclérose en plaques

Info

Publication number
MA32480B1
MA32480B1 MA33524A MA33524A MA32480B1 MA 32480 B1 MA32480 B1 MA 32480B1 MA 33524 A MA33524 A MA 33524A MA 33524 A MA33524 A MA 33524A MA 32480 B1 MA32480 B1 MA 32480B1
Authority
MA
Morocco
Prior art keywords
treatment
children
compositions
multiple sclerosis
sclerosis
Prior art date
Application number
MA33524A
Other languages
Arabic (ar)
English (en)
Inventor
Marie-Claude Bastien
John Kovarik
Robert Schmouder
Olivier David
Goeril Karlsson
Thomas Bouillon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40974366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32480(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32480B1 publication Critical patent/MA32480B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comportent un composé de 2-amino-2-[2-(4-c2-20-alkyl-phényl)éthyl]propane-1,3-diol ou un sel de qualité pharmaceutique de celui-ci, et l'utilisation de celui-ci pour traiter, prévenir ou retarder la progression d'une sclérose en plaques chez un patient pédiatrique ou un patient souffrant d'un état précis.
MA33524A 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques MA32480B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13262108P 2008-06-20 2008-06-20
PCT/US2009/047885 WO2009155475A1 (fr) 2008-06-20 2009-06-19 Compositions pédiatriques pour le traitement de la sclérose en plaques

Publications (1)

Publication Number Publication Date
MA32480B1 true MA32480B1 (fr) 2011-07-03

Family

ID=40974366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33524A MA32480B1 (fr) 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques

Country Status (16)

Country Link
US (11) US20110152380A1 (fr)
EP (3) EP2303250A1 (fr)
JP (7) JP2011525189A (fr)
KR (4) KR20110020928A (fr)
CN (2) CN102076335A (fr)
BR (1) BRPI0914139A2 (fr)
CA (1) CA2728514C (fr)
CL (1) CL2010001463A1 (fr)
IL (2) IL209725A (fr)
MA (1) MA32480B1 (fr)
MX (1) MX2010014223A (fr)
NZ (1) NZ589618A (fr)
RU (1) RU2562571C2 (fr)
SG (1) SG10201406263SA (fr)
WO (1) WO2009155475A1 (fr)
ZA (1) ZA201008478B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155475A1 (fr) 2008-06-20 2009-12-23 Novartis Ag Compositions pédiatriques pour le traitement de la sclérose en plaques
CN104788325A (zh) * 2008-11-11 2015-07-22 诺华股份有限公司 芬戈莫德的结晶形式
US20100160259A1 (en) * 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
EP3831371A1 (fr) 2009-09-29 2021-06-09 Novartis AG Posologie d'un agoniste du récepteur s1p
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
EP3027174B1 (fr) * 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Compositions pharmaceutiques à base de fingolimod
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
BR9408323A (pt) 1993-12-17 1997-08-19 Sandoz Ag Derivados de rapamicina
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69624921T2 (de) 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
WO1998002441A2 (fr) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathogènes
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2002537294A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌ及びカテプシンｓの阻害剤としてのジ−及びトリペプチドニトリル誘導体
AU2560300A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
CA2360740A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1043027A1 (fr) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Traitement combiné de l'esclerose multiple avec l'interferon et l'hormone de croissance
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
WO2001019808A1 (fr) 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Composes et compositions chimiques et leur utilisation en tant qu'inhibiteurs de la cathepsine s
GB9930449D0 (en) 1999-12-23 2000-02-16 Promotion & Display Tech Ltd Handset
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
EP1309593B1 (fr) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Pyrazoles substitutes
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
US7589202B2 (en) 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
WO2002032879A1 (fr) 2000-10-19 2002-04-25 Naeja Pharmaceutical Inc. Derives de dihydropyrimidine utilises comme inhibiteurs de cysteine protease
WO2002051983A2 (fr) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Composes et compositions en tant qu'inhibiteurs de cathepsine
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
EP1434769A2 (fr) 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Composes utiles comme inhibiteurs reversibles de cysteine protease
CA2463770A1 (fr) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes convenant comme inhibiteurs reversibles de proteases de la cysteine
DE60225316T2 (de) 2001-11-13 2009-02-26 AXYS Pharmaceuticals, Inc., South San Francisco Cyanoalkylamino-derivate als protease-hemmer
EP1446392A1 (fr) 2001-11-14 2004-08-18 Aventis Pharmaceuticals, Inc. Nouveaux composes et compositions jouant le role d'inhibiteurs de cathepsine s
EP1389480A1 (fr) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Utilisation thérapeutique de guanylhydrazones pour l'inhibition des procédés dépendant du CD83 et de la maturation des cellules dendritiques
MXPA05003254A (es) * 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
CA2707750A1 (fr) 2003-04-08 2004-10-21 Novartis Ag Compositions pharmaceutiques solides contenant un antagoniste des recepteurs de la s1p et un alcool de sucre
US20050009052A1 (en) * 2003-04-22 2005-01-13 Irm Llc, A Delaware Limited Liability Company Differential tag length analysis of cell proliferation
WO2005025553A2 (fr) * 2003-09-12 2005-03-24 Neuronova Ab Traitement de maladies ou de lesions du systeme nerveux avec le fty720
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
RU2487703C2 (ru) 2006-09-26 2013-07-20 Новартис Аг Фармацевтические композиции, включающие модулятор s1р
WO2009155475A1 (fr) 2008-06-20 2009-12-23 Novartis Ag Compositions pédiatriques pour le traitement de la sclérose en plaques

Also Published As

Publication number Publication date
KR20110020928A (ko) 2011-03-03
US20200197334A1 (en) 2020-06-25
US20160022611A1 (en) 2016-01-28
US20190117593A1 (en) 2019-04-25
US20110152380A1 (en) 2011-06-23
US20170333368A1 (en) 2017-11-23
JP2011525189A (ja) 2011-09-15
JP2015107984A (ja) 2015-06-11
US20210023027A1 (en) 2021-01-28
SG10201406263SA (en) 2015-02-27
KR20160131126A (ko) 2016-11-15
IL209725A0 (en) 2011-02-28
JP2021152016A (ja) 2021-09-30
IL248919A0 (en) 2017-01-31
JP2017122106A (ja) 2017-07-13
JP2018184424A (ja) 2018-11-22
US20170128389A1 (en) 2017-05-11
CL2010001463A1 (es) 2011-05-06
RU2562571C2 (ru) 2015-09-10
AU2009259950A1 (en) 2009-12-23
IL209725A (en) 2016-11-30
NZ589618A (en) 2012-09-28
EP3545953A1 (fr) 2019-10-02
MX2010014223A (es) 2011-01-21
CA2728514A1 (fr) 2009-12-23
IL248919B (en) 2018-12-31
KR20170081755A (ko) 2017-07-12
US20180177747A1 (en) 2018-06-28
JP2023153786A (ja) 2023-10-18
CA2728514C (fr) 2020-08-11
CN102076335A (zh) 2011-05-25
US20130230489A1 (en) 2013-09-05
ZA201008478B (en) 2012-01-25
JP2020063269A (ja) 2020-04-23
WO2009155475A1 (fr) 2009-12-23
BRPI0914139A2 (pt) 2015-10-20
RU2011101771A (ru) 2012-07-27
KR20180017232A (ko) 2018-02-20
CN104800196A (zh) 2015-07-29
EP2303250A1 (fr) 2011-04-06
US20190358178A1 (en) 2019-11-28
US20160206574A1 (en) 2016-07-21
EP3011958A1 (fr) 2016-04-27

Similar Documents

Publication Publication Date Title
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
WO2010055028A3 (fr) Composés organiques
EP2249861A4 (fr) Traitement de maladies neurodégénératives avec de la progranuline (pgrn)
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
SI1824563T1 (sl) Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatične encefalopatije
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
MY148495A (en) Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
WO2010036395A3 (fr) Traitement de l’exposition aux organophosphates au moyen de composés de tétrahydroindolone arylpipérazine
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
WO2013098416A3 (fr) Composes anti-douleur
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
EP2667885A4 (fr) Compositions et procédés pour apporter ou moduler le goût sucré, et procédés de recherche systématique s'y rapportant
WO2012100043A3 (fr) Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
EA201170267A1 (ru) Способ лечения гиперчувствительности зубов
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
UA113975C2 (xx) Застосування фармацевтичної композиції або добавки, яка містить фосфатидилсерин і куркумін (варіанти)